GLP-1 drugs work for weight loss, study finds

As demand for weight-loss drugs rises, states grapple with Medicaid coverage
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles,
Ozempic 3.0? This drug causes the greatest weight loss — by far
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.
Some GLP-1s Achieve More Weight Loss Than Others: Study
Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts weigh the pros and cons of the practice.
Retatrutide outperforms Ozempic in weight loss, new study finds
Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks. Mimicking three hormones, it outperforms FDA-approved treatments like Ozempic and Wegovy.
IBX will no longer cover drugs like Ozempic when they are prescribed solely for weight loss
GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, whether they utilize weight loss drugs or not,” IBX said in a statement.
Ozempic: Beyond Diabetes, A Breakthrough for Weight Loss?
None
Health Matters: GLP-1 drugs work for weight loss, study finds
McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the medication to treat those who are overweight and obese among otherwise healthy patients.
FDA issues draft guidance on developing weight loss drugs
The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new document replaces an earlier draft guidance issued in February 2007. The new guidance stated that its focus is on the design of clinical trials and endpoints to demonstrate sustained weight loss,
Should Medicaid Pay for Ozempic and Other Weight-Loss Drugs?
With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, in November 2023. Although the new FDA green light doesn’t expand ...
CNBC on MSN18d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The Washington Post on MSN7d
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...